Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 10OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1CNS 1Breast 1

Conditions

Neoplasm Metastasis 1Meningeal Carcinomatosis 1Hormone Refractory Prostate Cancer 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × epothilone B × Clear all
NCT00450866 2014-02-28

Epothilone B in Treating Patients With CNS Metastases From Breast Cancer

Case Comprehensive Cancer Center

Phase 2 Completed
55 enrolled 12 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male, Meningeal Carcinomatosis

NCT00407251 2010-11-05

Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy

British Columbia Cancer Agency

Phase 2 Completed
73 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡